Arbutus Biopharma Corporation Common Stock
Veridion Score
Composite trend over time
Why is ABUS moving today?
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ABUS.
ABUS insider activity
Arbutus Biopharma Corporation Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ABUS.
ABUS contract awards, year to date.
Public federal awards linked to this ticker.
ABUS lobbying filings, year to date.
Registered lobbying filings matched to Arbutus Biopharma Corporation Common Stock.